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Summary The relationship between serum ceruloplasmin level and cancer incidence was investigated in a
case-control study nested within a longitudinal study of 39,268 Finns participating in the Social Insurance
Institution's Mobile Clinic Health Examination Survey carried out in 1968-1972. During a median follow-up
of 8 years, 766 cancer cases were identified. Ceruloplasmin levels were determined from stored serum samples
collected at the baseline from these cancer cases and from two matched controls per case. The overall
incidence of cancer was positively associated with serum ceruloplasmin level. The association was strongest for
lung cancer and other cancers related to smoking and, consequently, in males. The smoking-adjusted relative
risk of lung cancer among men was 4.3 (95% confidence interval (CI) = 1.8-10.6) in the highest quintile of
serum ceruloplasmin as compared with that in the lowest quintile. The corresponding relative risks for cancers
related to smoking combined, and for cancers not related to smoking were 3.9 (CI = 1.9-8.4) and 0.9
(CI = 0.6-1.5), respectively. The elevated risk of lung cancer at high concentrations of serum ceruloplasmin
persisted after further adjustment for several potential confounding factors such as serum levels of vitamins A
and E and selenium. The risk was stronger during the first 6 years of follow-up than later, and strongest
during the first 2 years. The most likely explanation of the present results thus is that high serum ceruloplas-
min levels in lung cancer are mainly due to occult cancer.
There is an association between high levels of serum copper
and the occurrence of cancer. Case-control studies nested
within cohort studies have reported an increased risk of
cancer in persons with initially high serum concentrations of
copper (Haines et al., 1982; Kok et al., 1988; Coates et al.,
1989). Elevated serum copper levels have also been found in
patients suffering from cancers at such diverse sites as the
breast, the lung, and gastrointestinal organs, and also in
leukaemia, lymphoma and melanoma (Fisher, 1979). Copper
levels have been higher in patients with advanced disease
than in those with less severe disease (Fisher, 1979). The
interpretation of this finding has been that elevated serum
copper levels may be secondary to cancer. In line with this
proposal one of the few cohort studies on serum copper and
cancer reported an elevated risk of cancer death associated
with high serum copper levels only during the first years of
follow-up (Coates et al., 1989). However, another study
showed that the excess risk persisted longer (Kok et al.,
1988), suggesting that serum copper level may be raised for
many years before diagnosis of the cancer.
The relation of copper to malignancy may be complex,
however. In accordance with the hypothesis that copper may
have an antioxidant effect and thus provide protection
against cancer, an increased risk of cancer has also been
observed in persons with low serum copper levels (Kok et al.,
1988). Furthermore, pharmacological doses of copper appear
to protect experimental animals against chemically induced
tumours (Committee on Diet ... 1982). Both deficiency and
excess of copper may thus be potentially harmful, and the
effects may not be similar for all sites of cancer (Molteni et
al., 1989). Not one of the few cohort studies conducted to
date (Haines et al., 1982; Kok et al., 1988; Coates et al.,
1989) has explored the possibility that the effect of copper
may differ from one cancer site to another. Studies of the
relationship between copper and cancer are still at a very
early stage, however. What is chiefly needed, therefore, is a
considerable increase in the amount of evidence available,
yielding essentially large enough numbers of cases of each
main type of cancer.
Most of the circulating copper is bound ceruloplasmin, a
cuproprotein that has been suggested to be a reliable measure
of copper status (Willett, 1990). We investigated the associa-
tion between serum ceruloplasmin concentration and subse-
quent short and long-term risk of cancers at different sites in
a prospective study of about 40,000 Finns.
Subjects and methods
Altogether 39,268 men and women, aged 15 years or over,
participated in the Social Insurance Institution's Health
Examination Survey carried out in 1968-1972 in various
parts of Finland (Aromaa, 1981). A self-completed question-
naire supplied information about occupation, previous and
current illnesses, medications, parity and smoking habits.
Height and weight were measured, and the body mass index
(weight/height2) was computed. Casual blood pressure was
recorded by the auscultatory method. Subjects with systolic
blood pressure > 160 and diastolic blood pressure
) 95 mmHg, and those taking antihypertensive drugs, were
described as hypertensive. The haematocrit level was deter-
mined by the Clay-Adams microhaematocrit method. Serum
cholesterol concentrations were determined after 1-3 weeks
of storage (at - 20°C) with an autoanalyser modification of
the Liebermann-Burchard reaction. The serum samples were
kept at - 20°C until they were thawed for ceruloplasmin,
selenium, beta-carotene, retinol, retinol-binding protein and
alpha-tocopherol analyses in 1983.
Information about incident cancer cases diagnosed during
the follow-up between the date of examination and the end
of December 1977 was obtained from the nationwide Finnish
Cancer Registry (Teppo et al., 1980). Virtually all cancer
cases occurring in Finland are reported to this registry. In-
formation about the site of primary cancer and about the
date of cancer diagnosis was linked with the data set of the
Social Insurance Institution's Health Examination Survey
using the unique personal identification number of the people
involved. The cancers were coded according to the Interna-
tional Classification of Diseases, Seventh Revision (ICD 7).
A case-control design was adopted, and two controls per
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case were selected by individual matching using sex,
municipality and age as matching factors (Knekt et al.,
1988). The controls were drawn from the same municipality
as the case, and matched for age as closely as possible.
Matching by municipality controlled for both the time of the
baseline examination and for the duration of storage of the
serum samples. Controls were selected for each incident
cancer case at the point of time corresponding to the date of
cancer diagnosis. The group at risk from which the controls
were selected included all persons free of cancer by that date
and who had not already been selected as controls for
another cancer case. The final data set consisted of 766
cancer cases and 1,419 controls.
The serum samples for each cancer case and the matched
controls were analysed in random order. The concentration
of serum ceruloplasmin and retinol-binding protein was
determined by the immunodiffusion technique (Boehring
Diagnostics, Hoechst, Germany). Short and long-term
repeatability of the serum ceruloplasmin level was estimated
from serum samples taken 4-8 months and 4-7 years after
the baseline examination. The intraclass correlation
coefficients of short-term repeatability were 0.77 and 0.34,
respectively. Both differed significantly from zero. The levels
of retinol, beta-carotene and alpha-tocopherol in serum were
determined simultaneously using high-pressure liquid
chromatography (Aaran & Nikkari, 1988). The concentration
of serum selenium was determined by a graphite furnace
atomic absorption spectrometric method (Alfthan & Kum-
pulainen, 1982).
The correlation ratios between the serum ceruloplasmin
level and various baseline characteristics in the control group
were estimated using the general linear model (Cohen &
Cohen, 1975). The association between serum ceruloplasmin
level and the risk of cancer was determined with the condi-
tional logistic model (Breslow & Day, 1980). Adjustment for
potential confounding factors was performed by including
them in the model. Relative risks (estimated as odds ratios)
were computed for quintiles of adjusted serum ceruloplasmin
levels. Statistical significances were tested with the likelihood
ratio test based on the model.
Results
The mean levels of potential confounding factors among
cases and controls are presented in Table I. There were more
smokers among cancer cases than among controls, and the
cases generally had lower levels of serum micronutrients than
the controls. The female cases had fewer childbirths than the
controls. Serum ceruloplasmin level was positively correlated
with age, varied by geographical area, and was higher among
smokers than among non-smokers in both sexes (Table II).
The crude mean serum level of ceruloplasmin was
371 mg 1' among all male cancer cases, which was statis-
tically significantly higher (P <0.001) than the mean of
354 mg 1` in the controls (Table III). The difference between
the cases and control means was greatest for lung cancer.
Similar differences occurred for some other cancers related to
Table I Means and standard deviations (SD) of potential confounders among cancer cases and controls
Men Women
Cases Controls Cases Controls
(n = 453) (n =841) (n = 313) (n = 578)
Percentage Percentage
Variable Mean SD Mean SD difference Mean SD Mean SD difference
Age 58.4 12.1 58.3 12.0 + 0.2 56.1 14.6 56.0 14.6 + 0.2
Body mass index (kgm2) 25.1 3.5 25.8 2.9 - 2.7 26.9 4.4 27.1 3.6 - 0.7
Haematocrit (vol %) 45.4 3.7 45.8 2.3 - 0.9 42.0 3.0 42.2 2.3 - 0.5
Serum cholesterol (mgdl-') 264 50 269 57 - 1.9 275 65 277 45 - 0.7
Serum selenium (uig 1') 60.5 17.5 64.1 15.4 - 5.6 65.9 16.8 65.6 13.7 + 0.5
Serum beta-carotene (jug I-') 72.3 57.4 84.1 77.6 - 14.0 119.5 98.7 126.5 94.1 -5.5
Serum retinol (gI-gl ) 645 139 667 107 -3.3 587 135 604 108 -2.8
Serum retinol-binding 58.6 12.8 60.2 8.9 - 2.7 49.1 9.6 49.9 6.7 - 1.6
protein (mg-1')
Serum alpha-tocopherol (mgI1') 8.0 2.6 8.3 2.2 - 3.6 10.0 3.1 10.4 2.9 - 2.9
Parity (% with >4 childbirths) . 27.0 32.8 - 17.7
Current smoker (%) 58.3 41.5 + 40.5 12.8 10.7 + 19.6
High blood pressure (%) 16.8 18.4 - 8.7 27.8 27.3 + 1.8
Table II Multiple partial correlation coefficientsa between serum ceruloplasmin
level and potential confounding factors in the control group
Men (n =841) Women (n = 578)
Correlation Correlation
Variable coefficient P valueb coefficient P valueb
Age + 0.16 <0.001 0.13 <0.01
Geographical area 0.18 <0.001 0.19 0.001
Occupation 0.12 <0.01 0.07 0.64
Smoking + 0.24 <0.001 + 0.06 0.74
Body mass index - 0.16 <0.001 + 0.09 0.04
Blood pressure classification - 0.07 0.22 + 0.12 0.04
Haematocrit - 0.01 0.79 + 0.04 0.38
Serum cholesterol + 0.02 0.66 + 0.01 0.74
Serum beta-carotene - 0.08 0.03 - 0.05 0.22
Serum retinol -0.04 0.30 + 0.14 <0.001
Serum retinol-binding protein - 0.07 0.06 + 0.15 <0.001
Serum alpha-tocopherol + 0.05 0.13 + 0.10 0.01
Serum selenium + 0.05 0.12 + 0.15 <0.001
Parity + 0.03 0.50
aAdjusted for age. bTest for difference from zero.294 P. KNEKT et al.
smoking (e.g., cancer of the urinary organs), for all cancers
related to smoking combined, and for lymphomas and
leukemias. A similar finding was observed in women for lung
cancer only.
The smoking-adjusted relative risks of cancer between
quintiles of serum ceruloplasmin presented similar associa-
tions as the crude results (Table IV). While little association
was observed in women, there was a significant positive
gradient in men between serum ceruloplasmin level and the
occurrence of all sites of cancer, with a relative risk of 1.4
(95% confidence interval (CI) = 1.0-2.1) between the highest
and lowest quintiles. The corresponding risks were greater
for lung cancer and cancers related to smoking, i.e., 4.3
(CI = 1.8-10.6) and 3.9 (CI = 1.9-8.4), respectively. By con-
trast, the corresponding relative risk of cancers unrelated to
smoking combined was 0.9 (95% confidence interval =
0.6-1.5). Adjustment for smoking, serum cholesterol,
haematocrit, body mass index, occupation, parity in women,
alpha-tocopherol, beta-carotene, retinol, retinol-binding pro-
tein and selenium did not materially change the results, the
relative risk of lung cancer, smoking-related cancers com-
bined and cancers unrelated to smoking combined being 3.5
(CI= 1.3-9.3), 3.9 (CI= 1.7-9.0), and 0.9 (CI=0.5-1.8),
respectively.
No interaction between smoking and serum ceruloplasmin
was observed. In fact, the relative risk of cancer was similar
among non-smoking and smoking men in respect to cancers
related to smoking and cancers unrelated to smoking (Table
V). The number of current smokers among women was too
small to give any reliable results.
In order to investigate whether the association between
ceruloplasmin and cancer might be due to occult cancer, the
association was studied separately for the first 6 years and
the later years of follow-up (Table VI). The significantly
elevated risk of cancer at all sites, smoking-related cancers
combined and lung cancer at high levels of serum ceruloplas-
Table III Serum ceruloplasmin cancer case mean and mean of the mean case-control differences for different primary cancer sites
Men Women
Case Case- Case Case-
No. of mean control P value No. of mean control P value
Site of cancer sets (mg -') difference for trend sets (mg l-') difference for trend
All sites 453 371 +17 <0.001 313 411 -6 0.38
Stomach 48 347 - 16 0.19 28 421 + 1 0.96
Colorectal 21 340 - 15 0.31 35 418 - 11 0.72
Pancreas 17 381 + 34 0.31 11 393 - 4 0.81
Lung 144 391 + 39 <0.001 8 461 + 34 0.21
Prostate 37 361 + 3 0.89
Breast 67 405 - 12 0.48
Cervix uteri 23 401 - 37 0.12
Endometrium 12 436 + 42 0.24
Ovary 16 376 - 13 0.55
Urinary organs 26 387 +33 0.12 9 412 -4 0.75
Skin: basal cell carcinoma 49 344 - 6 0.59 38 416 - 5 0.71
Lymphomas and leukaemia 19 367 + 25 0.14 13 442 0 0.99
Other or unspecified cancers 92 371 + 17 <0.05 53 406 - 2 0.95
Related to smokinga 185 387 + 36 <0.001 24 430 + 2 0.85
Unrelated to smokingb 268 359 + 4 0.39 289 410 - 7 0.34
aIncludes cancers of the lip, oral cavity, and pharynx (International Classification of Diseases, Seventh Revision codes 140-148), oesophagus
(code 150), respiratory organs (codes 160-163), and urinary bladder (code 181). bIncludes cancers other than those listed in the footnote
immediately above.
Table IV Smoking-adjusted relative risk between quintiles (1 = lowest,
different primary cancer sites
5 = highest) of serum ceruloplasmin for
Men Women
Relative risk (by quintilea) Relative risk (by quintilea)
P value P value
Site of cancer 1 2 3 4 5 for trend 1 2 3 4 5 for trend
All sites 1.0 0.8 1.3 1.4 1.4 0.001 1.0 1.0 0.9 0.8 0.9 0.37
Stomach 1.0 0.2 0.8 0.9 0.4 0.20 1.0 0.9 0.7 0.9 1.0 0.86
Colorectal 1.0 0.1 1.7 0.5 0.4 0.38 1.0 0.8 0.5 0.7 0.8 0.72
Pancreas 1.0 1.3 1.2 1.0 1.7 0.31 + + + + + 0.92
Lung 1.0 2.0 3.5 2.5 4.3 <0.001 + + + + + 0.45
Prostate 1.0 0.4 0.2 0.7 0.6 0.96
Breast 1.0 0.9 1.3 0.6 0.7 0.48
Cervix uteri 1.0 1.0 1.7 0.4 0.5 0.08
Endometrium 1.0 0.0 0.9 0.0 4.9 0.23
Ovary 1.0 1.1 1.7 0.8 0.0 0.52
Urinary organs + + + + + 0.07 + + + + + 0.70
Skin: basal cell carcinoma 1.0 0.8 1.3 0.6 1.0 0.69 1.0 0.5 0.5 0.6 0.3 0.60
Lymphomas and leukaemia 1.0 0.8 0.5 2.4 2.4 0.11 1.0 1.4 0.0 1.0 0.4 0.72
Other or unspecified cancers 1.0 0.9 1.5 1.9 1.4 0.14 1.0 1.1 0.8 1.3 1.0 0.86
Related to smokingb 1.0 1.8 3.7 2.4 3.9 <0.001 1.0 8.1 4.8 4.2 1.3 0.91
Unrelated to smokingc 1.0 0.6 0.9 1.1 0.9 0.44 1.0 0.9 0.8 0.8 0.9 0.33
aThe quintiles are based on the distribution of values (mgl1') among controls (, 300, 301-330, 331-360,
361 -400, and >401 in men and < 350, 351 -390, 391 -420, 421 -480, and ) 481 in women). "Includes cancers of
the lip, oral cavity, and pharynx (International Classification of Diseases, Seventh Revision codes 140-148),
oesophagus (code 150), respiratory organs (codes 160-163), and urinary bladder (code 181). clncludes cancers other
than those listed in the footnote immediately above. + The iteration did not converge.SERUM CERULOPLASMIN AND RISK OF CANCER 295
Table V Relative risk (95% confidence interval) of cancer between the four highest and the lowest
quintiles of serum ceruloplasmin in non-smokers and current smokers
Related to smoking' Unrelated to smokingb
95% 95%
Smoking No. of Relative confidence No. of Relative confidence
Sex status sets risk interval sets risk interval
Men Non-smoker 36 3.0 (1.0-9.0) 153 0.8 (0.5-1.2)
Current smoker 149 2.4 (1.1-5.0) 115 0.9 (0.5-1.7)
Women Non-smoker 16 2.2 (0.4-11.9) 253 0.9 (0.6-1.3)
Current smoker 4 + + 36 0.5 (0.2-1.4)
aIncludes cancers of the lip, oral cavity, and pharynx (International Classification of Diseases,
Seventh Revision codes 140-148), oesophagus (code 150), respiratory organs (codes 160-163), and
urinary bladder (code 181). bIncludes cancers other than those listed in the footnote immediately
above. + The iteration did not converge.
Table VI Smoking-adjusted relative risk (95% confidence interval) of all sites of cancer, lung cancer, smoking related cancers and smoking
unrelated cancers between quintiles of serum ceruloplasmin for different durations of follow-up among men
All sites Lung Smoking related' Smoking unrelatedc
Quintile Duration offollow-up Duration offollow-up Duration offollow-up Duration offollow-up
of serum <6 yrs >6 yrs <6 yrs >6 yrs <6 yrs >6 yrs <6 yrs >6 yrs
ceruloplasmina (n = 358) (n = 95) (n = 112) (n = 32) (n = 141) (n = 44) (n = 217) (n = 51)
1 (lowest) 1 1 1 1 1 1 1 1
2 0.7 1.1 1.2 8.6 1.1 4.3 0.6 0.7
(0.4-1.0) (0.5-2.3) (0.4-3.5) (0.8-89.7) (0.5-2.8) (1.0-19.2) (0.3-0.9) (0.3-1.8)
3 1.2 1.8 3.3 7.2 2.9 8.9 0.9 1.0
(0.8-1.9) (0.8-4.1) (1.1-9.4) (0.5-113.7) (1.2-7.2) (1.4-55.6) (0.5-1.6) (0.4-2.7)
4 1.6 0.5 2.9 1.1 2.5 1.2 1.3 0.3
(1.1-2.4) (0.2-1.2) (1.1-7.5) (0.1-17.3) (1.1-5.5) (0.2-6.6) (0.8-2.2) (0.1-1.0)
5 (highest) 1.6 0.6 6.6 1.1 5.3 1.2 0.9 0.8
(1.1-2.5) (0.2-1.5) (2.4-18.4) (0.1-17.4) (2.2-12.8) (0.2-7.2) (0.5-1.6) (0.2-2.6)
P value for trend <0.001 0.56 <0.001 0.69 <0.001 0.90 0.33 0.55
aThe quintiles are based on the distribution of values (mg I-') among controls (4 300, 301-330, 331-360, 361-400, and >401). bIncludes
cancers of the lip, oral cavity, and pharynx (International Classification of Diseases, Seventh Revision codes 140-148), oesophagus (code 150),
respiratory organs (codes 160-163), and urinary bladder (code 181). cIncludes cancers other than those listed in the footnote immediately
above.
min was mainly confined to the beginning of the follow-up
and it was strongest during the first 2 years. In the first 2
years the relative risks of all sites of cancer, lung cancer,
smoking-related cancers and cancers unrelated to smoking
between the highest and lowest quintiles of serum ceruloplas-
min were 2.7 (1.3-5.6), 12.9 (1.6-104.2), 7.4 (1.4-38.3), and
1.7 (0.7-4.0), respectively. On the other hand, a non-
significant inverse association was observed during the later
years of follow-up.
Discussion
In the present study, men initially free of cancer and with a
high level of serum ceruloplasmin subsequently had an excess
risk ofcancer. This finding extends and corroborates those of
previous cohort studies showing an elevated overall risk of
cancer at high serum copper levels (Haines et al., 1982; Kok
et al., 1988; Coates et al., 1989). Due to the large cohort and
the complete coverage of the incident cancer cases in the
present study, it was possible to investigate the association
between serum ceruloplasmin level and cancer risk by site.
The association was confined to lung cancer and other
cancers related to smoking among men; a similar non-
significant result was observed among the few women with
lung cancer. Smoking was observed to be associated with an
elevated level of ceruloplasmin in the present study. This
relationship could not, however, explain the increased risk of
all smoking-related cancers combined. Furthermore, the
association of high serum ceruloplasmin level and smoking-
related cancers was also evident in non-smokers. The reason
why high ceruloplasmin should be a marker only of cancers
related to smoking remains unknown.
Ceruloplasmin is a protein transporting most of the cir-
culating copper and is thus highly correlated with serum
copper level (Solomons, 1985). The indices of copper status
are known to be sensitive to a number of external factors
(Willett, 1990). Accordingly, serum ceruloplasmin level in the
present study was associated with several potential con-
founders including nondietary factors such as smoking, body
mass index, occupation and parity on the one hand, and
nutrient-related factors such as serum cholesterol, retinol,
beta-carotene, alpha-tocopherol and selenium on the other.
Adjustment for these factors did not materially change the
results, suggesting that the association between ceruloplasmin
and cancer was not due to confounding by them. Nonethe-
less, the possibility of confounding by dietary, life-style and
physiological factors not studied cannot be ruled out.
Ceruloplasmin is one of the many 'acute phase reactant'
proteins synthetised in the liver in response to various
stimuli. Many of these internal and external stimuli resulting
in liver disorders may be related to acute or chronic infec-
tions, and several other conditions, including malignancy,
may similarly lead to increased synthesis of ceruloplasmin.
Accordingly, the serum ceruloplasmin level has been reported
to be raised in patients with cancer (Askari et al., 1980), and
to be higher in patients with advanced disease than among
those with less severe disease (Fisher, 1979). The results of
the present study suggest that the presence of cancer may
raise serum ceruloplasmin levels for several years before the
cancer is diagnosed: in agreement with one previous cohort
study (Coates et al., 1989), the cancer risk at high serum
ceruloplasmin levels was elevated mainly during the first 6
years of follow-up and the association was strongest during
the first 2 years. An elevated serum ceruloplasmin level could
thus be a marker for lung cancer, indicating the presence of
this disease up to several years before it is diagnosed. An
alternative interpretation is that high serum ceruloplasmin296 P. KNEKT et al.
actually is a risk indicator preceeding the cancer. Thus, the
positive association between serum ceruloplasmin level and
cancer risk is, in fact, present over the entire follow-up, but is
concealed during the last years of follow-up in the present
study because of the relatively low long-term reliability of
serum ceruloplasmin. This hypothesis is in agreement with
the finding from another earlier study, reporting the excess
risk associated with high serum copper level to have lasted
for a long period (Kok et al., 1988).
The association between copper and cancer may have
other implications, too. In agreement with the hypothesis
that copper may inhibit oxidative damage (Oberley & Buett-
ner, 1979), animal studies indicate that high doses of copper
may provide protection against some cancers (Committee on
Diet . . . 1982). Accordingly, in one of the previous studies
(Kok et al., 1988), a low level of copper was associated with
a moderate increase in cancer mortality. A similar non-
significant finding was observed in the present study after
exclusion of the first 6 years of follow-up. Thus, the lack of
an inverse association between the serum ceruloplasmin level
and cancer risk in the total sample of the present study does
not deny the possible importance of ceruloplasmin as an
antioxidant in cancer causation and prevention. The results
may merely reflect that the antioxidative effect of copper is
concealed by the elevation of the seruim copper level due to
occult cancer.
In conclusion, our findings suggest that high serum
ceruloplasmin concentrations during few years before diag-
nosis are associated with an increased risk of cancer,
especially of lung cancer. It is still conceivable that a high
serum ceruloplasmin concentration is a risk indicator
preceding cancer. However, the most likely explanation of
the findings is that a high serum ceruloplasmin concentration
is a sign of occult lung cancer.
This study was supported in part by a grant from the Cancer Society
of Finland and by Public Health Service Contract No. NO1-CN-
45165 from the Division of Cancer Prevention and Control, National
Cancer Institute of the United States.
References
AARAN, R.-K. & NIKKARI, T. (1988). HPLC method for the simul-
taneous determination of beta-carotene, retinol and alpha-
tocopherol in serum. J. Pharm. Biomed. Anal., 6, 853.
ALFTHAN, G. & KUMPULAINEN, J. (1982). Determination of
selenium in small volumes of blood plasma and serum by electro-
thermal atomic absorption spectrometry. Anal. Chim. Acta, 140,
221.
AROMAA, A. (1981). Epidemiology and public health impact of high
blood pressure in Finland. Helsinki, Finland: Social Insurance
Institution, Finland. Series AL: 17 (In Finnish with an English
summary).
ASKARI, A., LONG, C.L. & BLAKEMORE, W.S. (1980). Zink, copper,
and parenteral nutrition in cancer. A review. J. Parent. Ent.
Nutr., 4, 561.
BRESLOW, N.E. & DAY, N.E. (1980). Statistical Methods in Cancer
Research. Vol. 1. The analysis of case-control studies. IARC
Scientific Publications 32: Lyon.
COATES, R.J., WEISS, N.S., DALING, J.R., RETTMER, R.L. & WAR-
NICK, G.R. (1989). Cancer risk in relation to serum copper levels.
Cancer Res., 49, 4353.
COHEN, J. & COHEN, P. (1975). Applied Multiple Regression/
Correlation Analysis for the Behavioral Sciences. Wiley: New
York.
COMMITTEE ON DIET, NUTRITION, AND CANCER (1982).
Assembly of Life Sciences. National Research Council. Diet,
Nutrition and Cancer. National Academy Press: Washington, DC.
FISHER, G.L. (1979). Trace element interactions in carcinogenesis. In
Trace Metals in Health and Disease, Kharasch, N. (ed.)
pp. 93-107. Raven Press: New York.
HAINES, A.P., THOMPSON, S.G., BASU, T.K. & HUNT, R. (1982).
Cancer, retinol binding protein, zink and copper. Lancet, i, 52.
KNEKT, P., AROMAA, A., MAATELA, J. & 7 others (1988). Serum
vitamin E and risk of cancer among Finnish men during a
10-year follow-up. Am. J. Epidemiol., 127, 28.
KOK, F.J., VAN DUIJN, C.M., HOFMAN, A. & 4 others (1988). Serum
copper and zinc and the risk of death from cancer and cardiovas-
cular disease. Am. J. Epidemiol., 128, 352.
MOLTENI, A., WARD, W.F., KIM, Y.T. & 5 others (1989). Serum
copper concentration as an index of clinical lung injury. Adv.
Exp. Med. Biol., 258, 273.
OBERLEY, L.W. & BUETTNER, G.R. (1979). Role of superoxide dis-
mutase in cancer: a review. Cancer Res., 38, 1141.
SOLOMONS, N.W. (1985). Biochemical, metabolic, and clinical role of
copper in human nutrition. J. Am. Coll. Nutr., 4, 83.
TEPPO, L., PUKKALA, E., HAKAMA, M., HAKULINEN, T., HERVA, A.
& SAXEN, E. (1980). Way of life and cancer incidence in Finland.
A municipality-based ecological analysis. Scand. J. Soc. Med.
(suppl 19).
WILLETT, W. (1990). Nutritional Epidemiology. Oxford University
Press: New York.